Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Recurrent adverse cardiovascular events can occur despite dual antiplatelet therapy post-coronary stenting.
• Aspirin resistance is a significant factor contributing to treatment failure in these patients.
• Optimal antiplatelet strategies for aspirin-resistant patients undergoing coronary stenting remain unclear.

Purpose of the Study:

• To investigate the clinical impact of clopidogrel loading time on adverse cardiovascular events in patients with aspirin resistance.
• To determine if early clopidogrel administration improves outcomes compared to late administration in this specific patient group.

Main Methods:

• A total of 980 patients undergoing elective coronary stenting were enrolled.
• Patients were divided into early (<6 hours) and late (>6 hours) clopidogrel loading groups.
• Aspirin resistance was assessed using urinary 11-dehydrothromboxane B2 levels; 240 patients were identified as aspirin resistant.

Main Results:

• Among 240 aspirin-resistant patients, major adverse cardiac events occurred in 13.9% of the early-loaded group versus 25.8% in the late-loaded group (p=0.02).
• Early clopidogrel loading was an independent predictor of a lower rate of cardiac events (HR=0.46, p=0.001).
• Bleeding events and periprocedural myocardial infarction rates were comparable between the early- and late-loaded groups.

Conclusions:

• Administering clopidogrel earlier than 6 hours before elective coronary stenting benefits aspirin-resistant patients by reducing ischemic events.
• This early loading strategy is associated with similar bleeding rates, suggesting an improved risk-benefit profile.